<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36927191</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8409</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of clinical immunology</Title><ISOAbbreviation>Expert Rev Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Combination strategies for lupus nephritis: facts and controversies.</ArticleTitle><Pagination><StartPage>527</StartPage><EndPage>536</EndPage><MedlinePgn>527-536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/1744666X.2023.2192927</ELocationID><Abstract><AbstractText Label="INTRODUCTION">There is an unmet need to improve the efficacy of therapeutic regimens in lupus nephritis (LN). Cocktail immunosuppressive therapy for the synergistic effect of individual drugs may enhance efficacy and enable dosage reduction. However, the potential increase in the risk of serious and opportunistic infections is a concern. Moreover, the timing of combination therapy, adoption of a step-up or step-down approach, and the choice of drugs is still controversial, partly related to the cost-effectiveness issue.</AbstractText><AbstractText Label="AREAS COVERED">Evidence of a combination of conventional, newer immunosuppressive, and biologic/targeted agents in LN.</AbstractText><AbstractText Label="EXPERT OPINION">Early combination of conventional regimens with anti-B cell activation factor (anti-BAFF) or calcineurin inhibitors (CNIs) enhances the therapeutic effect without increasing serious adverse events in LN. However, combining anti-CD20 and anti-BAFF biologics appears to be less promising from the results of clinical trials. Initial combination strategy may be more cost-effective for patients at risk of treatment failure and renal function deterioration. With the availability of more options, the treat-to-target approach in LN is increasingly feasible and further studies are needed to compare the step-up and step-down approaches in the treatment of LN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chi Chiu</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-3696-1228</Identifier><AffiliationInfo><Affiliation>Departments of Medicine, Tuen Mun Hospital, Hong Kong, SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Clin Immunol</MedlineTA><NlmUniqueID>101271248</NlmUniqueID><ISSNLinking>1744-666X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-BAFF</Keyword><Keyword MajorTopicYN="N">Anti-CD20</Keyword><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">calcineurin</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>8</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36927191</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2023.2192927</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>